Cigna Corporation

🇺🇸New York Stock Exchange
Back to all articles
Cigna Corporation stock analysis CI overview
Bullish +65

The Cigna Group stock (US1255091092): Analyst consensus and valuation picture on NYSE CI - AD HOC NEWS

📊 CI shares trade in the high USD 280s, well below the consensus 12-month analyst price target of approximately USD 339.50.

🏆 The stock holds a 'Moderate Buy' rating from 21 research firms with an average objective substantially above current trading levels.

📉 CI has declined roughly 8% over the last 12 months but has gained about 3.9% year-to-date as of May 2026.

💰 The company maintains a market capitalization of approximately USD 75.7 billion on the New York Stock Exchange.

🧮 Discounted cash flow models estimate a fair value near USD 339.58, implying significant upside from current prices.

🏥 Cigna generates revenue primarily through U.S. medical insurance plans, pharmacy benefits, and integrated health services.

🌍 The stock is accessible to international investors via cross-border venues like Tradegate for trading in euros.

📈 Recent daily performance showed a single-session gain of about 1.75%, highlighting short-term volatility within the larger trend.

⚖️ The valuation debate centers on whether the current discount reflects sector risks or a genuine undervaluation opportunity.

Bullish Signals
  • Analyst consensus is 'Moderate Buy' with an average 12-month price target of USD 339.50, significantly higher than the current trading range.
  • Discounted cash flow analysis suggests a fair value of roughly USD 339.58 per share, indicating the stock may be undervalued.
  • The company has achieved positive year-to-date performance with a gain of approximately 3.9% despite a negative 12-month trend.
  • CI is an S&P 500 constituent, providing exposure to a large-cap U.S. health care leader with a substantial market cap of USD 75.7 billion.
  • The stock trades below many analysts' targets, potentially offering a margin of safety for value-oriented investors.
Risk Factors
  • The stock has experienced an 8% decline over the last 12 months, indicating recent downward pressure on the share price.
  • The mixed performance pattern with year-to-date gains offsetting annual losses suggests ongoing volatility in investor sentiment.
Full Analysis
The Cigna Group (CI) shares on the New York Stock Exchange are currently trading in the high USD 280s, significantly below the consensus analyst price target of approximately USD 339.50. As of May 28, 2026, major brokerages maintain a 'Moderate Buy' stance, suggesting the stock is undervalued relative to its intrinsic worth according to multiple models. Recent performance data indicates a mixed trajectory for the health insurer. While CI has gained roughly 3.9% year-to-date as of May 22, 2026, it has declined about 8% over the past 12 months. The company maintains a market capitalization of roughly USD 75.7 billion and operates primarily in the U.S. medical insurance and pharmacy benefits sectors. Valuation analysis from late May 2026, including discounted cash flow assessments by Simply Wall St, estimates a fair value around USD 339.58 per share. This creates a substantial gap between current market pricing and forward-looking intrinsic value models, positioning CI as a potential opportunity for investors despite recent short-term volatility and sector-specific risks. The stock's valuation narrative is framed by modest year-to-date gains against a backdrop of a pullback over the last year. Investors are weighing whether the discount to target prices reflects genuine sector risks or represents an undervalued entry point, with future performance dependent on operating results and broader U.S. health care policy dynamics.